Welcome to the CNN Philippines Presidential Debate. Nine presidential candidates gather in a live debate to face the nation as they strive to chart the country’s future. Moderated by Pia Hontiveros and Pinky Webb, this Comelec-accredited debate is presented in partnership with the University of Santo Tomas and Microsoft Philippines, in cooperation with Kapisanan ng […]
ANKARA, Turkey – November 20, 2022 – (Newswire.com)
Digital health start-up H2o therapeutics received 510(k) marketing clearance from the U.S. Food and Drug Administration for its prescription mobile app Parky for monitoring Parkinson’s Disease. Parky App monitors symptoms such as tremors and dyskinesia in real-time via the use of the Apple Watch. It is a tool for sharing meaningful and reliable data between patients and medical professionals regarding the course of the disease.
The app leverages the Movement Disorder API, a tool developed by Apple. The API was validated in a study of 343 participants, including longitudinal tracking of 225 participants for up to six months and used the clinical gold standard (MDS-UPDRS) as a reference. Details of the study were published in Science Translational Medicine last year.
10 million patients worldwide live with Parkinson’s Disease, the fastest-growing neurological disorder. Healthcare professionals in this area need reliable feedback and data for optimized treatment plans. Parky App helps medical professionals to develop a clinical profile of the patient while outside of the clinic. The Parky App strengthens the possibility of data-driven, tailored treatment procedures and bridges the gap between real-life and in-clinic settings.
“As a woman-founded, non VC-backed company based in Turkey, receiving our first 510(k) clearance is a huge milestone for us. We believe Parky will bring great value to the Parkinson’s Disease community as an easily scalable and data-driven product,” Yagmur Selin Gulmus, the founder of h2o therapeutics, said in a statement. The company has 2 more digital therapeutics products in the pipeline based on wearable devices and FDA submissions are planned to be completed in 2023.
h2o therapeutics is developing digital therapeutics with a focus on mobile technologies, Augmented Reality (AR), and Artificial Intelligence (AI). h2O intends to make real-time human data become a handy tool for disease management in certain therapeutic areas. Their core understanding of digital therapeutics lies in the power of AI, the robustness of their clinical health research, and high levels of user engagement.
Contact Information:
Yagmur Selin Gulmus
Founder
[email protected]
Hande Erciyes
Operations Manager
[email protected]
Press Release Service
by
Newswire.com
Original Source:
H2o Therapeutics Gets FDA Clearance for Its Apple Watch-Based App for Parkinson’s Disease
Japan’s number of children has been reported to be at its lowest since 1950. There are just 14.6 million children in the nation under the age of 14, according to figures from Japan’s internal affairs ministry. Japan’s falling birth rate and high life expectancy is putting pressure on public spending and resulting in labour shortages. […]
Employees allege firing after religious exemptions to covid shot mandate were denied
BOSTON – Nove…
Altrua Ministries in Action
Altrua HealthShare + Jordan Feliz + Danny Gokey + Convoy of Hope Donation Presentation of check Danny Gokey and Jorda…
Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness.
NEW YORK – November 17, 2022 – (Newswire.com)
In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer, cancer treatments, and clinical research with “I Have Cancer,” the company’s new social media campaign. “I Have Cancer” will focus on the problems experienced by cancer patients and their loved ones while bringing attention to the importance of cancer prevention. The campaign will also provide up-to-date information about oncology clinical trials for cancer patients interested in pursuing innovative new treatments. Massive Bio, based in New York City, uses a proprietary artificial intelligence platform called SYNERGY-AI to match cancer patients to clinical trials.
“This project is very important for society,” says Erkan Terzi, Global Marketing Vice President for Massive Bio and one of the architects of the “I Have Cancer” campaign. “We have cancer awareness, but the problem is how much we understand cancer and cancer patients. Millions of people die from cancer yearly, and everyone is at risk of getting cancer. With this project, we want to raise cancer awareness, show how we can protect ourselves and our loved ones, and provide information about cancer treatments.”
“Clinical milestones include working with physicians, pharmaceutical and genomic testing providers, and hospitals, as well as our network of oncology clinical trial registration opportunities in Europe and South America,” said Çağatay Çulcuoğlu, co-founder, CFO, and COO of Massive Bio. “We have expanded our patient-engagement activities through advocacy groups, webinars, and the publication of Massive Bio magazine, which informs readers about the latest news in cancer research and clinical trials. Now, with our ‘I Have Cancer’ campaign, we aim to be the voice of patients and their families who need support and are not heard but who want to share their experiences and ideas to build a better tomorrow for future generations.”
The “I Have Cancer” campaign, which will launch in November with posts on Massive Bio’s social media channels, will emphasize the theme that cancer patients are not alone. The importance of cancer foundations and associations will also be highlighted in the campaign, carried out simultaneously on Facebook, Instagram, TikTok, Twitter, LinkedIn, and YouTube. The campaign will use the hashtags #ihavecancer, #cancerawareness, and #massivebio to help cancer patients and their supporters make their voices heard. The campaign will continue until the end of May.
About Massive Bio
Massive Bio’s mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations, and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific data-driven patient recruitment, site selection, and AI-based trial pre-screening services.
Contact Information:
merve sahin
PR Executive
+1 844 627 7246
Press Release Service
by
Newswire.com
Original Source:
Massive Bio Launches ‘I Have Cancer’ Campaign
U.S. hospitals and healthcare systems gain access to expanded toolset for driving compliance to CMS & OIG regulations.
SpendMend SpendMend
…
Data, Measurement, and Reporting Key to Building a Comprehensive Healthcare System Growth Strategy
LOUISVILLE, Ky. – November 17, 2022 – (Newswire.com)
HSG Advisors, a healthcare consultancy that supports health system leaders with data intelligence to strategically improve employed physician network performance, has published a white paper in Texas Healthcare Trustees’ Governance Resources, Strategy. The publication outlines “Best Practices in Patient Attraction and Retention Growth Strategies” and was created to outline best practices for measuring, reporting, and building a comprehensive growth strategy as healthcare consumption continues to shift to a predominantly outpatient experience.
Health systems continue to operate in a predominantly fee-for-volume world while slowly transitioning towards a fee-for-value environment. Having strategies to maximize the attraction of new patients and increase retention of current patients is critical if hospitals and healthcare systems are to be successful. To survive in both volume and value-based environments, organizations are looking for best practices to develop a strategy that supports each mode of operation while ensuring patients receive proper care at the right time and location.
“True growth is going to be driven from the top down with physicians, advanced practice providers, service line leaders, inpatient and outpatient service operators, and front staff employees being the real change agents,” stated white paper author and Managing Director at HSG Advisors, DJ Sullivan. “The groups must have consistent and reliable data on referral sources, geographic opportunities and influencers, and primary and urgent care needs if they are going to be able to make decisions that will support long-term organizational goals,” Sullivan added.
Best practices for hospitals and health systems to track success in both operating environments include having access to metrics that are easy to interpret and update. By identifying the right key performance indicators, healthcare executives can better ensure that patients receive timely and informed care while meeting goals that support patient attraction and retention.
The HSG Advisors’ white paper provides an outline of the following best practices for hospitals and healthcare systems as they navigate patient attraction and retention:
For more information on applying the practices illustrated in the white paper to healthcare organizations, contact DJ Sullivan at 502-814-1198 or email [email protected]. The white paper “Best Practices in Patient Attraction and Retention Growth Strategies” is available for download at HSGAdvisors.com.
Contact Information:
Karolyn Raphael
PR for HSG Advisors
312-494-0422
Press Release Service
by
Newswire.com
Original Source:
HSG Advisors Publishes Best Practices in Patient Attraction and Retention for Hospitals and Healthcare Systems White Paper
Shamima Begum, who fled the UK and joined the Islamic State group when she was a teenager, was smuggled into Syria by an intelligence agent for Canada. Ms Begum was 15 when she and two other east London schoolgirls travelled to Syria to join the IS group in 2015. Files seen by the BBC show […]
PORTLAND, Maine – November 16, 2022 – (Newswire.com)
Glacial Multimedia …
Copyright © 2024 | WordPress Theme by MH Themes